|
AU6344998A
|
|
Pharmaceutical formulations containing poorly soluble drug substances
|
|
CA2281807A1
|
|
Method of treating a tumor
|
|
MX9710225A
|
|
Calpain inhibitors for the treatment of neurodegenerative diseases.
|
|
US5827850A
|
|
1,2,4-benzotriazine oxides formulations
|
|
US5776987A
|
|
Pharmaceutical suspension formulation
|
|
US5760056A
|
|
Pharmaceutical formulation
|
|
WO9711699A1
|
|
1,2,4-benzotriazine oxides formulations
|
|
CN1177963A
|
|
6-aryl pyrazolo [3, 4 -d] pyrimidin -4 -ones and compositions and methods of use thereof
|
|
CN1177960A
|
|
6-substituted pyrazolo (3, 4 -d) pyrimidin -4 ones and compositions and methods of use thereof
|
|
NZ303886A
|
|
1-cyclopentyl (or tert butyl)-6-aryl (or heteroaryl)-pyrazolo[3,4-d]pyrimidin-4-one derivatives and medicaments
|
|
AU4987096A
|
|
Hypodermic syringe holder with disposable body
|
|
AU4927096A
|
|
Low friction coating for cartridge seal cap
|
|
US5653698A
|
|
Coupling systems for saftey cannula
|
|
US5665760A
|
|
Lyophilized thioxanthenone antitumor agents
|
|
US5872207A
|
|
N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
|
|
WO9641638A1
|
|
Calpain inhibitors for the treatment of neurodegenerative diseases
|
|
US5656288A
|
|
Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
|
|
AU2547895A
|
|
Therapeutic phenoxyalkylheterocycles
|
|
HU9602985D0
|
|
Halomethyl amides as il-1beta protease inhibitors and pharmaceutical compositions containing them
|
|
US5656629A
|
|
6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
|
